BidaskClub lowered shares of Albireo Pharma (NASDAQ:ALBO) from a strong-buy rating to a buy rating in a research report released on Monday morning.
A number of other research analysts also recently commented on the company. Jefferies Financial Group initiated coverage on Albireo Pharma in a report on Friday, April 20th. They issued a buy rating and a $50.00 price objective on the stock. Zacks Investment Research upgraded Albireo Pharma from a sell rating to a hold rating in a report on Friday, March 30th. Wedbush reiterated an outperform rating and issued a $63.00 price objective on shares of Albireo Pharma in a report on Wednesday, March 28th. Needham & Company LLC initiated coverage on Albireo Pharma in a report on Thursday, March 15th. They issued a buy rating and a $50.00 price objective on the stock. Finally, ValuEngine upgraded Albireo Pharma from a buy rating to a strong-buy rating in a report on Wednesday, May 2nd. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. The company has a consensus rating of Buy and a consensus target price of $58.80.
Albireo Pharma opened at $33.43 on Monday, according to Marketbeat.com. Albireo Pharma has a one year low of $15.31 and a one year high of $39.87. The stock has a market capitalization of $388.47 million, a PE ratio of -10.61 and a beta of 1.47.
Albireo Pharma (NASDAQ:ALBO) last released its quarterly earnings data on Thursday, May 17th. The biopharmaceutical company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of $3.75 by ($3.90). The firm had revenue of $11.20 million during the quarter, compared to analyst estimates of $55.33 million. sell-side analysts forecast that Albireo Pharma will post -3.13 earnings per share for the current year.
In related news, COO Jan Mattsson sold 25,000 shares of the firm’s stock in a transaction that occurred on Wednesday, June 13th. The stock was sold at an average price of $32.26, for a total transaction of $806,500.00. Following the transaction, the chief operating officer now owns 43,538 shares in the company, valued at approximately $1,404,535.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 3.60% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in the stock. Millennium Management LLC grew its stake in Albireo Pharma by 234.0% during the 1st quarter. Millennium Management LLC now owns 155,611 shares of the biopharmaceutical company’s stock worth $5,068,000 after buying an additional 109,017 shares during the last quarter. Element Capital Management LLC purchased a new position in Albireo Pharma during the 1st quarter worth approximately $335,000. Eversept Partners LLC purchased a new position in Albireo Pharma during the 1st quarter worth approximately $587,000. Tibra Equities Europe Ltd purchased a new position in Albireo Pharma during the 1st quarter worth approximately $590,000. Finally, Heartland Advisors Inc. purchased a new position in Albireo Pharma during the 1st quarter worth approximately $2,974,000. Hedge funds and other institutional investors own 54.77% of the company’s stock.
Albireo Pharma Company Profile
Albireo Pharma, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate includes A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating progressive familial intrahepatic cholestasis and phase II clinical trial for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases.
Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.